The history of Sildenafil presents a complex picture for shareholders. While the initial introduction generated substantial gains, the end of its patent opened the avenue to off-brand versions, dramatically diminishing https://brightbookmarks.com/story21859087/the-copyright-and-big-pharma-a-risky-investment